Abstract library

546 results for "Radiolabelled somatostatin antagonist".
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt
#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients
Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Guillaume Nicolas
#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Guillaume Nicolas
Keywords: PRRT, 177Lu, OPS201
#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues
Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Shi Y, ...
#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Alberto Carmona-Bayonas
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt
#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Daria Handkiewicz-Junak
Keywords: CgA, PRRT, prognosis
#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study
Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: dr Sara Massironi
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#2754 Somatostatin Analogs (SSA) in Patients with Symptomatic Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)
Introduction: DIPNECH is characterized by a proliferation of pulmonary neuroendocrine cells and multifocal neuroendocrine tumorlets and/or tumors. Although usually indolent, DIPNECH can cause chronic cough and dyspnea. There is very limited information on treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr. Jonathan Strosberg